Malignant conversion of florid oral and labial papillomatosis during topical immunotherapy with imiquimod

被引:13
作者
Wenzel, K
Saka, B
Zimmermann, R
Gundlach, KKH
Barten, M
Gross, G
机构
[1] Univ Rostock, Fac Med, Dept Dermatol & Venerol, D-18055 Rostock, Germany
[2] Univ Rostock, Dept Maxillofacial Surg, Rostock, Germany
[3] Univ Rostock, Inst Pathol, Rostock, Germany
关键词
florid oral papillomatosis; papillomatosis of the lip; topical immunotherapy; imiquimod; squamous-cell carcinoma;
D O I
10.1007/s00430-002-0172-8
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We report a case of a 61-year-old woman suffering from florid oral papillomatosis with a squamous-cell cancer of the floor of the mouth, which was removed by scalpel surgery combined with a radical neck dissection in 1996. Between 1996 and 2000 several histologically benign papillomatous lesions of mouth and lips were removed with laser and electrosurgery. However, the lesions recurred. In July 2000 hyperkeratotic, wart-like lesions were present at the lower and upper lips and at the right angle of the mouth and the adjacent oral mucosa. Overnight treatment with a topical 5% imiquimod cream on a Monday-Wednesday-Friday schedule was initiated. However, due to severe irritation and pain the application had to be reduced to 4 h per night, three times a week, followed by a therapy-free interval of 2 weeks. Despite this treatment consisting of four cycles of 3 weeks (1 week treatment and 2 weeks pause), the lesions increased markedly in size. A biopsy taken from the tumorous lesion from the right angle of the mouth proved to be a squamous-cell carcinoma. The tumors of the labial and oral mucosal sites as well as the right submandibular lymph nodes were removed by wide scalpel excision. The lips were reconstructed by plastic surgery. 24 months after surgical intervention no recurrence nor metastasis to lymph nodes or distal sites were observed.
引用
收藏
页码:161 / 164
页数:4
相关论文
共 36 条
[1]   Enhancement of the innate and cellular immune response in patients with genital warts treated with topical imiquimod cream 5% [J].
Arany, I ;
Tyring, SK ;
Stanley, MA ;
Tomai, MA ;
Miller, RL ;
Smith, MH ;
McDermott, DJ ;
Slade, HB .
ANTIVIRAL RESEARCH, 1999, 43 (01) :55-63
[2]   Dermal dendritic cells in anogenital warty lesions unresponsive to an immune-response modifier [J].
Arrese, JE ;
Paquet, P ;
Claessens, N ;
Piérard-Franchimont, C ;
Piérard, GE .
JOURNAL OF CUTANEOUS PATHOLOGY, 2001, 28 (03) :131-134
[3]   Proliferative verrucous leukoplakia and its related lesions [J].
Batsakis, JG ;
Suarez, P ;
El-Naggar, AK .
ORAL ONCOLOGY, 1999, 35 (04) :354-359
[4]   Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream [J].
Beutner, KR ;
Geisse, JK ;
Helman, D ;
Fox, TL ;
Ginkel, A ;
Owens, ML .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1999, 41 (06) :1002-1007
[5]  
BURG G, 1990, HAUTARZT, V41, P314
[6]   The imidazoquinolines, imiquimod and R-848, induce functional, but not phenotypic, maturation of human epidermal Langerhans' cells [J].
Burns, RP ;
Ferbel, B ;
Tomai, M ;
Miller, R ;
Gaspari, AA .
CLINICAL IMMUNOLOGY, 2000, 94 (01) :13-23
[7]   CONCURRENT VERRUCOUS CARCINOMAS OF THE LIP AND BUCCAL MUCOSA [J].
CANNON, CR ;
HAYNE, ST .
SOUTHERN MEDICAL JOURNAL, 1993, 86 (06) :691-693
[8]  
Davis G, 2000, J REPROD MED, V45, P619
[9]  
Diaz-Arrastia C, 2001, CLIN CANCER RES, V7, P3031
[10]   Self-administered topical 5% imiquimod cream for external anogenital warts [J].
Edwards, L ;
Ferenczy, A ;
Eron, L ;
Baker, D ;
Owens, ML ;
Fox, TL ;
Hougham, AJ ;
Schmitt, KA .
ARCHIVES OF DERMATOLOGY, 1998, 134 (01) :25-30